Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users

Sidney, Stephen; Cheetham, T. Craig; Connell, Frederick A.; Ouellet‐Hellstrom, Rita; Graham, David J.; Davis, Daniel; Sorel, Michael; Quesenberry, Charles P.; Cooper, William O.

doi:10.1016/j.contraception.2012.09.015

Cited by 105 publications

(78 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…153 The patch has undergone multiple label revisions, most recently August 22, 2012. The 2012 package insert contains a black box warning citing 5 US studies [163][164][165][166][167][168][169][170] (1 with statistically significant findings) that suggest a possible increased risk of VTE compared with a 20-to 35-μg COC, with odds ratios of 1.2 to 2.2. Although these potential health risks are concerning to some adolescents, the patch remains an important contraceptive alternative that may be the best option for some adolescents, especially in comparison with the many adverse consequences of unplanned pregnancy, which include an increased risk of VTE.…”

Section: Pediatrics Volume 134 Number 4 October 2014 E1267mentioning

confidence: 99%

Contraception for Adolescents

Ott

Sucato²

2014

Pediatrics

244

133

View full text Add to dashboard Cite

A working knowledge of contraception will assist the pediatrician in both sexual health promotion as well as treatment of common adolescent gynecologic problems. Best practices in adolescent anticipatory guidance and screening include a sexual health history, screening for pregnancy and sexually transmitted infections, counseling, and if indicated, providing access to contraceptives. Pediatricians’ long-term relationships with adolescents and families allow them to help promote healthy sexual decision-making, including abstinence and contraceptive use. Additionally, medical indications for contraception, such as acne, dysmenorrhea, and heavy menstrual bleeding, are frequently uncovered during adolescent visits. This technical report provides an evidence base for the accompanying policy statement and addresses key aspects of adolescent contraceptive use, including the following: (1) sexual history taking, confidentiality, and counseling; (2) adolescent data on the use and side effects of newer contraceptive methods; (3) new data on older contraceptive methods; and (4) evidence supporting the use of contraceptives in adolescent patients with complex medical conditions.

show abstract

Section: Pediatrics Volume 134 Number 4 October 2014 E1267mentioning

confidence: 99%

Contraception for Adolescents

Ott

Sucato²

2014

Pediatrics

244

133

View full text Add to dashboard Cite

show abstract

“…The study revealed that vaginal ring use and combined oral contraceptive pill use were associated with statistically similar venous and arterial thromboembolic risks during routine clinical use [11]. A Food and Drug Administration-funded retrospective cohort study using data from four health plans further indicated that users of the NuvaRing showed similar thromoembolic events as those who used oral contraceptive pills [12]. In contrast to the studies mentioned above, only one research report using a statically relevant patient population has revealed a small increased risk of venous thromboses in users specifically of the NuvaRing compared to combined oral contraceptives [13].…”

mentioning

confidence: 97%

The $100 million question: Does NuvaRing Usage Result in increased cardiovascular dysfunction?

Bryan¹

2014

Angiol

View full text Add to dashboard Cite

“…Arterial thrombotic events such as heart attack and stroke, and venous thromboembolism are more common with combined ethinyl estradiol and drospirenone, and have similar incidence in users of vaginal ring, contraceptive skin patches or lowdose ethinyl estradiol pills compared to non-users. [9][10][11] Women older than 35 years and smokers have formal contraindication to combined hormonal methods due to increased risk of thromboembolic events. 9,10 Control of bleeding is one of the benefits of using combined hormonal contraceptives, also in women with uterine myomas and adenomyosis.…”

Section: Introductionmentioning

confidence: 99%

“…[9][10][11] Women older than 35 years and smokers have formal contraindication to combined hormonal methods due to increased risk of thromboembolic events. 9,10 Control of bleeding is one of the benefits of using combined hormonal contraceptives, also in women with uterine myomas and adenomyosis. 1 For those who prefer to menstruate less often or not to menstruate, there is the option of extended system, which consists of continuous use of combination pills.…”

Section: Introductionmentioning

confidence: 99%

Contraception and family planning at the extreme of reproductive life – climacteric

Bella

Bianchi

Araújo

et al. 2016

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Menopause is an endocrine phenomenon characterized by gradual estrogen decline. This is a stage in a woman's life in which contraception is extremely important as the risks associated with pregnancy and childbirth increase, both maternal issues associated with higher incidence of comorbidities and issues related to fetal abnormalities, mitochondrial abnormalities, or genetic syndromes. On the other hand, there is a growing number of women who have postponed motherhood and need effective contraception, but without prolonging the return to fertility. Long-acting reversible contraceptives (LARCs), low-dose oral hormonal contraceptives and non-oral contraceptives are preferred. The levonorgestrel-releasing intrauterine system is a very good alternative that can maintain endometrial protection after menopause. Definitive methods such as tubal ligation and vasectomy are options for couples that already have their offspring. In this review, we present evidence for contraceptive indication and the effects of hormonal methods on climacteric including options for contraception, control of bleeding during perimenopause and of climacteric symptoms, as well as the transition from such methods to hormone therapy if indicated.

show abstract

Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users

Cited by 105 publications

References 20 publications

Contraception for Adolescents

Contraception for Adolescents

The $100 million question: Does NuvaRing Usage Result in increased cardiovascular dysfunction?

Contraception and family planning at the extreme of reproductive life – climacteric

Contact Info

Product

Resources

About